Abstract
Prior studies have demonstrated a decreased humoral response in solid organ transplant recipients (SOTRs) to SARS-CoV-2 mRNA vaccination (17% antibody response after dose 1, 54% after dose 2) as compared to the general population (100%). However, these studies were dominated by kidney transplant recipients, and included only a small percentage of liver transplant (LT) recipients (19.6%).(1-4) Since LT recipients often receive milder induction and maintenance immunosuppression, they may have a more robust humoral response. To investigate this, we studied SARS-CoV-2 antibody development in a cohort of LT recipients who completed a two-dose mRNA vaccine series of either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
